Acceleron Pharma Inc - Articles and news items

FDA Fast Track designation granted to luspatercept for the treatment of patients with beta-thalassemia

Industry news / 18 May 2015 / Victoria White

The FDA has granted Fast Track designations to luspatercept for two separate indications for the treatment of patients with beta-thalassemia…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+